Join
Live feed
·
PRReleasevia Quantisnow
Puma Biotechnology Inc logo

Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor

ByQuantisnow·Wall Street's wire, on your screen.
PBYI· Puma Biotechnology Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PBYI (Puma Biotechnology Inc) and more on Quantisnow.